ReviewCell communication and signaling : CCS2025
F-box proteins in cancer: from cancer cells to the tumor microenvironment.
Review in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The role of the WD40-repeat protein family in cancer.Molecular cancer · 2026Review
- FBXO39 promotes LDHA-mediated aerobic glycolysis and colorectal cancer progression by p53 degradation.Journal of translational medicine · 2026Article
- Structure-Based Virtual Screening of New Skp1 Inhibitor Chemotypes Targeting F-Box Binding Interface.Drug design, development and therapy · 2026Article
- FUT2 enhances anti-tumor immunity in pancreatic cancer radiotherapy by driving FBXO2-mediated degradation of NR2F2.Cell death & disease · 2025Article
- FBXO9 promotes anti-tumor immunity via degradation of PD-L1 in pancreatic cancer.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
F-box proteins have been well-established as important regulators of cancer development after decades of exploration. As the understanding of cancer biology continues to deepen, novel biological characteristics of cancer cells have been incorporated, and the perspective has expanded from cancer cells themselves to a more complex tumor microenvironment (TME). In this context, F-box proteins form an extensive and multi-layered regulatory network to fine-tune diverse biological events, not only within cancer cells, but also in the TME. Therefore, in this review, we summarize the functional and mechanistic paradigms of F-box proteins in both cancer cells and the TME, and underscore their adaptability and wide coverage on the basis of a sophisticated regulatory hierarchy, presenting the clinical prospects of F-box proteins as potential targets for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.